INTRODUCTION {#sec1-1}
============

Acute pulmonary embolism (PE) is the third common cardiovascular causes of hospital admission and mortality, following stroke, and acute coronary syndrome. Predictors of mortality following acute PE include: Simultaneous malignancy, chronic pulmonary disease, age older than 70 years, systemic hypotension at time of admission, heart failure, right ventricular akynesia and dysfunction, and biomarkers such as B-type natriuretic peptide and cardiac troponins.\[[@ref1][@ref2][@ref3]\]

Among hospitalized patients, hyponatremia is a common electrolyte abnormality, and recent data showed that it had associated with poor outcome in patients with acute and chronic cardiovascular and pulmonary diseases, like heart failure, acute myocardial infarction and parenchymal lung infection. Besides in patients with cirrhosis and ascites while waiting for a liver transplant, hyponatremia is a great predictor of death.\[[@ref1][@ref2][@ref4]\]

Our purpose was to evaluate the association between hyponatremia following admission and 1-month mortality of patients with acute PE. If found, this routinely available low cost laboratory finding, may be used in determining prognostic indexes of patients with acute PE.

MATERIALS AND METHODS {#sec1-2}
=====================

This is a cohort single center study conducted in a Tertiary Referral Medical Hospital in Center of Iran from March 2012 to March 2014.

Study patients {#sec2-1}
--------------

252 consecutive patients with confirmed diagnosis of PE admitted our hospital were included in this study and prospectively followed. The final outcome and prognosis were evaluated during the course of hospitalization and within 30 days of initial presentation.

Inclusion criteria {#sec2-2}
------------------

Evidence of PE should be documented by either computed assisted tomography pulmonary angiography or by ventilation/perfusion pulmonary scintigraphy besides clinical and investigational evidence in favor of the diagnosis in the absence of an alternative one.

Exclusion criteria {#sec2-3}
------------------

Patients who were not definitively diagnosed as having PE were excluded from this study.

Definition of hyponatremia and outcomes {#sec2-4}
---------------------------------------

The hyponatremia was defined in our study as a baseline serum sodium level 137 mmol/L or lower. Sodium level between 135 and 137 was considered mild hyponatremia and amounts of sodium bellow 135 had severe hyponatremia.\[[@ref3]\]

Our study outcome was pulmonary emboli related mortality within 30 days of initial presentation.

Clinical and demographic variables {#sec2-5}
----------------------------------

At time of patients arrival in our hospital with suspicious to PE, a detailed medical history was obtained through a standardized questionnaire containing specific questions about symptoms, presence of known risk factors such as: Use of hormone replacement therapy, pregnancy or oral contraceptives, concomitant malignancy, recent trauma or surgery within the last 4 weeks, complete bed rest for \>3 days, concurrent diseases, and medication use. In addition, variables such as hemoptysis prior to medication, altered menal status, New York Heart Association class, mode, and duration of predominant symptoms such as, chest pain, abdominal pain, fatigue, palpitations, dizziness, syncope, orthopnea, cough, and cyanosis at presentation and overt right ventricular failure prior the onset of symptoms and clinical signs included mean systolic blood pressure (SBP) and diastolic blood pressure, shock index (heart rate/SBP), hypoxemia, and evidence of deep venous thrombosis were considered. Severity of the PE was evaluated by PE severity index (PESI), a confirmed prognostic model for patients with PE.\[[@ref5][@ref6][@ref7][@ref8]\] We also used the simplified PESI (sPESI) format,\[[@ref9]\] which are included: History of malignancy, chronic cardiopulmonary disease, age \>80 years, pulse \>110 beats/min, SBP \<100 mmHg, and SpO~2~ \<90%.

Statistical analyses {#sec2-6}
--------------------

In order to compare baseline characteristics for patient discharges across three levels of serum sodium (\<135, 135-137, and \>137 mmol/L), we applied Kruskal-Wallis test for contiguous variables and Chi-square test for categorical variables. We used the log-rank test and survival analyses to compare the cumulative 1-month mortality by sodium level, and stratified our evaluations of mortality by plasma sodium level and original PESI severity and its sPESI sub-classes.

In order to evaluate the relation between plasma sodium level and mortality, we also used logistic regression analysis with adjusting for patient severity of illness by using all PESI severity models.

Ethics {#sec2-7}
------

The study method was approved by the Isfahan University Medical Ethics Review Committee, and all participants consciously signed a written consent. In this scheme, any intervention by the research team could not be applied and patients were treated under view of healthcare team and according to the protocol in the emergency department of the hospital.

RESULTS {#sec1-3}
=======

Two hundred fifty-two patients with confirmed diagnosis of PE (59% men, median age of 56 years, and mean age 59 years ranging from 19 to 95 years) were evaluated. We excluded 16 (6.5%) patients for missed next their follow-up, 6 (2.4%) patients refused to participate to this study, and 6 (2.4%) patients were died not correlated to PE or its side effect. The study cohort included 224 patient admitted with a diagnosis of acute PE from Alzahra University Hospitals; 109 patients (48.7%) had normal sodium level (serum level \>137 mmol/L). 115 patients had sodium level below 137 mmol/L. Of these, 56 (25%) had a sodium level 135-137 mmol/L, and 59 (26.3%) had a sodium level below 135 mmol/L. Primary patient characteristics by level of serum sodium are noted in [Table 1](#T1){ref-type="table"}.

###### 

Primary patient characteristics by level of serum sodium

![](JRMS-20-777-g001)

Association between plasma sodium level and 1 month mortality {#sec2-8}
-------------------------------------------------------------

Overall, 53 of 224 patients (23.6%) died at the end of 30 days. As shown in [Figure 1](#F1){ref-type="fig"}, patients with a serum sodium level of \>137, 135-137, and \<135 mmol/L had a cumulative 1-month mortality of 14%, 21%, and 42% (*P* \< 0.0001), respectively.

![Kaplan-Meier estimates of cumulative 30-day mortality for patients with pulmonary embolism by baseline level of serum sodium](JRMS-20-777-g002){#F1}

After adjustment of patient for severity of PE by PESI risk class, mortality was also significantly higher in patients with lower serum sodium level \[[Table 2](#T2){ref-type="table"}\].

###### 

Mortality and level of serum sodium stratified by severity of illness (PESI)

![](JRMS-20-777-g003)

When the sPESI risk class was evaluated, the 30-day mortality remained significantly increased for patients with sodium level lower than 135 mmol/L \[[Table 3](#T3){ref-type="table"}, [Figure 2](#F2){ref-type="fig"}\]. In order to omitted the role of some confounding variables such as history of cancer, heart failure, renal failure, or chronic obstructive pulmonary disease, all of them were excluded from analysis, but the mortality was still significantly different \[[Figure 3](#F3){ref-type="fig"}\].

###### 

Level of serum sodium and 30 days mortality stratified by severity of illness

![](JRMS-20-777-g004)

![Kaplan-Meier estimates of 30-day mortality and level of serum sodium stratified by severity of illness in high risk patients (high score pulmonary embolism severity index) (*P* \< 0.05)](JRMS-20-777-g005){#F2}

![Kaplan-Meier estimates of 30-day mortality by level of serum sodium in patients with pulmonary embolism without chronic heart failure, chronic obstructive pulmonary disease, chronic renal failure, and cancer, the cumulative mortality was 56.2, 25, and 18.8% for patients with a sodium level. \<135, 135-137, and, ≥138 mmol/l (*P* \< 0.002)](JRMS-20-777-g006){#F3}

DISCUSSION {#sec1-4}
==========

According to our results, a significant proportion of patients with PE (26.3%) is hyponatremic (serum sodium \<135 mmol/L) at the time of presentation. Serum sodium \<135 mmol/L was observed in only approximately 2% of the community subjects, but associated with a 3.5-fold increased incidence of adverse outcome.\[[@ref5]\] Among the patients with PE and hyponatremia, had significant higher 30-days mortality than patients without hyponatremia (42% for sodium level below 135 mmol/L vs. 14% for sodium level more than 137 mmol/L). So, severity of hyponatremia could increase mortality.

Our findings show that the mortality of patients with high PESI score and low sodium level was about 3 times over normonatremic (serum sodium \>137 mmol/L) group. So, it seems that we could be able to use sodium level as a prognostic factor in patients with PE. There are no another papers about using this factor in determination of mortality in these patients.

With exclusion of some confounding variables such as: Chronic lung disease, previous history of cancer, renal failure, or heart failure the results remained similar. So, hyponatremia adversely affects outcomes across the all subclasses in severity of illness (PESI risk classes I-V), even with exclusion of the lower-risk patients (low PESI score), the mortality was significantly increased. In addition, some studies show that mild hyponatremia in the general population associated with increased mortality.\[[@ref6][@ref7]\] According to these it seems that hyponatremia is an independent predictor of short-term mortality in PE.

Hyponatremia can be an indicator of severity of disorders, which may be predictive of however not causally related to mortality. In the patients with cardiovascular disease, hyponatremia may suggestive of significant physiologic abnormalities (e.g., low effective circulating volume with consequent disturbances of renal filtration rate and distal sodium delivery, raised levels of arginine vasopressin, or neurohormonal activation).\[[@ref4]\] Hyponatremia is a significant indicator of heart failure severity with poor prognosis.\[[@ref5][@ref8][@ref9]\] Besides, in patients with cirrhosis and ascites while waiting for a liver transplant, hyponatremia is a great predictor of death. Adding hyponatremia to the model for end-stage liver disease (MELD) score is a better predictor of death than the MELD score alone, especially in patients with low MELD scores. Interestingly, correction of hyponatremia in these patients may not improve prognosis after liver transplantation.

In order to explain increased 1-month mortality among the PE patients with hyponatremia, we first point to relation between hyponatremia and sympathetic nerves hyper activity. In patients with left ventricular dysfunction, hyponatremia is an indicator of neurohormonal activation. It might cause release of vasopressin leading to hyperactivity of the sympathetic and renin-angiotensin aldosterone system axis.\[[@ref1]\] Neurohormonal activation was also seen in patients with pulmonary arterial hypertension and right ventricular dysfunction.\[[@ref1][@ref10]\] So, as showed in two previous studies, in the setting of PE-related pulmonary arterial hypertension with right heart dysfunction, hyponatremia may initiated the neurohormonal activation, and finally resulted in increased mortality of patients with PE.\[[@ref11][@ref12]\]

Chronic inflammation may lead to production of interleukin-6 at inflammatory lesions, which can stimulate an excessive secretion of antidiuretic hormone resulting in hypochloremia and hyponatremia.\[[@ref5]\] Despite all these, recent hyponatremia treatment guidelines stated that "hyponatremia remains incompletely understood because of its association with a plethora of underlying disease states, and its multiple etiologies with differing pathophysiologic mechanisms."\[[@ref13]\]

Some studies about chronic heart failure show that correction of hyponatremia by use of vasopressin antagonists does not improve outcome in general,\[[@ref5]\] but other studies had different consequences.\[[@ref8][@ref14]\] Similar findings about pulmonary embolism are not available and prospective studies are necessary to determine whether correcting of hyponatremia improves outcomes or not.

Finally, more information is needed for using of serum sodium levels along with other known items of severity, in determining the prognosis of patients with pulmonary embolism.

Study limitations {#sec2-9}
-----------------

Due to referrals role of our hospital, a measure of actual samples of selected patients may not accessible, and this may cause increase mortality of patients in this study compared to other studies.In our patients, serum sodium levels after discharge were not checked. So, the role of persistent hyponatremia vs. temporary hyponatremia cannot be evaluated.In this study, the role of hyponatremia correction and modalities of PE treatment on prognosis are not assessed.
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